Table 3.
Multivariate analysis of disease-free survival (DFS) and overall survival (OS) in 5,433 women with HER2-negtive breast cancer
| B coefficients | Standard error | Wald | P | Hazard ratio | 95.0% confidence interval | |||
|---|---|---|---|---|---|---|---|---|
| Lower | Upper | |||||||
| DFS | ER + PR+ vs. ER-PR+ | 1.463 | .429 | 11.608 | 0.001 | 4.319 | 1.861 | 10.020 |
| ER + PR+ vs. ER-PR- | .913 | .170 | 28.982 | 0.000 | 2.493 | 1.788 | 3.476 | |
| ER + PR+ vs. ER + PR- | .753 | .291 | 6.702 | 0.010 | 2.123 | 1.201 | 3.755 | |
| ER-PR- vs. ER-PR+ | .550 | .422 | 1.695 | 0.193 | 1.733 | .757 | 3.963 | |
| ER-PR- vs. ER + PR- | -.160 | .296 | .293 | 0.589 | .852 | .477 | 1.523 | |
| OS | ER + PR+ vs. ER-PR+ | 1.977 | .761 | 6.755 | 0.009 | 7.220 | 1.626 | 32.061 |
| ER + PR+ vs. ER-PR- | 1.774 | .307 | 33.488 | 0.000 | 5.895 | 3.232 | 10.751 | |
| ER + PR+ vs. ER + PR- | 1.564 | .478 | 10.722 | 0.001 | 4.779 | 1.874 | 12.189 | |
| ER-PR- vs. ER-PR+ | .203 | .728 | .078 | 0.781 | 1.225 | .294 | 5.105 | |
| ER-PR- vs. ER + PR- | -.210 | .462 | .207 | 0.649 | .811 | .328 | 2.004 | |
(Adjusted for age, stage, nuclear grade and Ki-67).